Form 4: Olema Pharmaceuticals Director Gorjan Hrustanovic Acquires 23,000 Stock Options

Director Gorjan Hrustanovic acquired 23,000 stock options in Olema Pharmaceuticals, according to a recent SEC filing.

Summary

• Gorjan Hrustanovic, a director of Olema Pharmaceuticals, acquired 23,000 stock options on June 14, 2024.
• The exercise price of these options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, and fully vest at the next annual meeting if not fully vested before, contingent on continuous service.
• Hrustanovic is a member of BVF Partners L.P. and will transfer any economic benefit from the sale of shares to BVF, disclaiming beneficial ownership except for any pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option grants, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, common in the pharmaceutical industry as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Pfizer also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, aligning with industry standards for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment to the company's success.

Key Dates